Belite Bio BLTE
NASDAQ BLTE
$186.65 +15.56 (+9.09%)
As of: Sep 4, 2026 · 1:37 PM EDT

Belite Bio (BLTE) Income from Non-Controlling Interests (2024 - 2026)

Analysis

Belite Bio (BLTE) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 139.31 Bn 131.46 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.65 Bn 77.66 Bn 3.93 Bn -
3 Argenx Se 63.46 Bn 58.27 Bn 1.37 Bn -
4 Moderna 57.94 Bn 52.80 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - -
6 BeOne Medicines 39.96 Bn 34.86 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.16 Bn 31.85 Bn 992.69 Mn -
8 Royalty Pharma 28.44 Bn 27.60 Bn - 63.60 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn -
10 Belite Bio 6.28 Bn 6.28 Bn - -6.78 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6.78 Mn
Mar 31, 2026 -13.20 Mn
Dec 31, 2025 -11.72 Mn
Sep 30, 2025 41.49 Mn
Jun 30, 2025 -7.62 Mn
Mar 31, 2025 -6.67 Mn
Dec 31, 2024 -4.21 Mn